Latest news with #MZGroup
Business Wire
22-07-2025
- Business
- Business Wire
Cabbacis Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
BUSINESS WIRE)--Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name (the 'Company'), today announced the engagement of international investor relations specialists MZ Group ('MZ') to lead a strategic investor relations and financial communications program across all key markets. Joseph Pandolfino, Chief Executive Officer of Cabbacis (OTCQB: CABI), stated, "Our breakthrough iBlend product design positions us for success as we move toward commercialization. We look forward to working with the MZ Group team during this pivotal time." The Company's management will work closely with MZ Group to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community. The initiative will highlight how Cabbacis is developing harm-reduction products with its iBlend™ cigarettes and vaporizer pods for the world's accelerating one-trillion-dollar tobacco and nicotine market consisting of one billion smokers. A recent example are the results of the Company's successful, pilot clinical trial, which were reported last week; the trial measured the perceptions and effects on smokers of using four types of reduced-nicotine tobacco cigarettes made by Cabbacis. With a robust worldwide patent portfolio comprising 35 issued product patents including 7 in the United States, an experienced management team, and an established production facility, Cabbacis is poised to leverage and scale a first-to-market advantage for iBlend™ products combining reduced-nicotine tobacco and hemp ahead of the potential implementation of the proposed rule of the U.S. Food and Drug Administration ('FDA') for a nicotine cap on all cigarettes sold in the United States. MZ has developed a distinguished reputation as a premier resource for institutional investors, brokers, analysts and private investors. Lucas A. Zimmerman, Managing Director at MZ North America, and Ian Scargill, Senior Vice President at MZ, will provide guidance to Cabbacis on corporate and financial communications, including roadshow and investment conference coordination in key financial hubs, to enhance visibility of the Company and the iBlend™ brand through financial and social media channels. Zimmerman commented, 'The global tobacco market is expected to grow to $1.1 trillion by 2030 with increasing demand for reduced-risk products, according to Research and Markets. In the United States, if the FDA's proposed nicotine cap for cigarettes is finalized and implemented, other countries are expected to follow the FDA's policy, which could drive an overnight shift in the dynamics of the global tobacco market. This would generate a compelling first-to-market advantage for Cabbacis and would force the tobacco industry to seek new alternatives, which will create an exciting market opportunity for the Company's flagship iBlend products.' Scargill added, 'The iBlend botanical blends predominately contain reduced-nicotine tobacco and include low-THC and no-THC hemp (<0.3% THC), which renders the iBlend brand relevant to consumers and differentiated compared to other tobacco products. Hemp is not intoxicating and is legal nationwide under the 2018 Farm Bill. The nicotine level in iBlend™, an approximate 95% reduction from the average nicotine content found in popular cigarette brands, positions the brand to meet the FDA's proposed nicotine cap. The Company's patent portfolio covering cigarettes and vaporizer pods provides a broad intellectual property moat for the Cabbacis products. The Company already has an established production facility in place, including the required licenses, to currently provide significant revenue and can easily be expanded to meet future demand growth.' Joseph Pandolfino, Chief Executive Officer of Cabbacis, added, "Our breakthrough iBlend product design positions us for success as we move toward commercialization. The FDA's proposed nicotine cap, if implemented, will create an urgent and significant need for compliant alternatives, as switching to less harmful products will become a necessity for many. We expect to file our first FDA Premarket Tobacco Product Application (PMTA) in late 2025, and in parallel to the FDA process for the U.S. market, we plan to start marketing our products internationally. We look forward to working with Lucas, Ian and the entire MZ Group team as we strive to deliver sustainable, long-term value to our shareholders." For more information on Cabbacis, please visit the Company's website: To schedule a conference call with management, please email your request to CABI@ or call Lucas Zimmerman at 949-259-4987. About MZ Group MZ North America is the U.S. division of MZ Group, a global leader in investor relations with over 250 employees and 800 clients across 12 different exchanges. For over 25 years, MZ has implemented award winning programs and developed a reputation for delivering tangible results for public and private companies via strategic communications, industry-leading investor outreach, public relations, a market intelligence desk, and a suite of technology solutions, spanning websites, conference call/webcasting, video production and XBRL/Edgar filing services. MZ maintains a global footprint with professionals located throughout every time zone in North America, as well as Taipei and São Paulo. For more information, please visit About Cabbacis Cabbacis (OTCQB: CABI) is focused on commercializing groundbreaking, patented harm-reduction tobacco products for the world's one billion smokers. Led by its flagship iBlend™ reduced-nicotine cigarettes and vaporizer pods in development, the Company is well positioned ahead of the proposed FDA rule to cap the nicotine content in all U.S. cigarettes. iBlend™ predominately contains tobacco combined with non-intoxicating hemp to assist in smoking or vaping less, transitioning to less harmful tobacco products, and/or increasing quit attempts. The Company also plans to commercialize reduced-nicotine tobacco cigarettes and little cigars without hemp and vaporizer pods with conventional-nicotine tobacco and hemp. In a recent clinical trial reported by the Company, Cabbacis cigarettes were highly rated for satisfaction and significantly reduced cravings for usual brand cigarettes. Cabbacis holds a global patent portfolio of 35 issued patents and various pending patent applications – primarily covering tobacco-hemp combinations in cigarettes and vaporizer pods – across key markets including the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico and Brazil – where approximately two-thirds of the world's smokers collectively reside. To learn more, please visit or follow us on LinkedIn or X. Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," 'consider,' "continue," "could," "estimate," "expect," 'foresee,' "intend," 'likely,' "may," "objective," "potential," "plan," "predict," "project," "seek," 'should,' "will" and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in 'Risk Factors' in our Regulation A Offering Circular qualified by the SEC on June 3, 2025 and in our Annual Report on Form 1-K for the period ended December 31, 2024 filed with the SEC. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of that state or jurisdiction.
National Post
16-05-2025
- Business
- National Post
Almonty Industries Reports First Quarter 2025 Financial Results
Article content TORONTO — Almonty Industries Inc. ('Almonty' or the 'Company') (TSX: AII / ASX: AII / OTCQX: ALMTF / Frankfurt: ALI), a leading global producer of tungsten concentrate, today announced its first quarter 2025 financial results. Article content Article content Key First Quarter 2025 & Subsequent Operational Highlights: Article content Secured binding offtake agreement with a U.S. defense contractor to supply tungsten oxide solely for U.S. defense applications. Obtained shareholder approval for a proposed domestication from Canada to the United States to empower Almonty's long-term competitiveness and support U.S. industry in light of global geopolitical tensions, with 99.6% of votes cast in favor. Advancing final preparations ahead of an expected near-term operations startup at the Company's Sangdong Tungsten Mine in South Korea, where processing equipment has been installed and the final drawdown of the US$75.1 million KfW IPEX-Bank project loan facility has been completed. Secured strategic partnership with American Defense International, a prominent government relations firm, supporting Almonty's position as a leading allied supplier of tungsten to the American defense and technology industries. Engaged international investor relations specialists MZ Group ('MZ') to lead a comprehensive, strategic investor relations and financial communications program across all key markets. Article content Revenue recorded in the first quarter of 2025 increased by 1.3% to $7.9 million, as compared to $7.8 million in the same year-ago quarter. The slight increase was largely attributable to higher tungsten concentrate sales, driven by a combination of lower production volumes and improved pricing under long-term supply agreements. Article content Income from mining operations in the first quarter of 2025 increased 24.1% to $0.75 million, as compared to $0.61 million in the same year-ago quarter. The increase was largely attributable to increased production at the Panasqueira mine as well as improved pricing. Article content Operating expenses in the first quarter of 2025 totaled $9.5 million, as compared to $4.3 million in the same year-ago quarter. The change in operating expenses was chiefly due to an increase in non-cash share-based compensation expense, non-cash loss on valuation of embedded derivative liabilities, and an increase in costs associated with the Company's proposed redomiciling. Article content Net loss in the first quarter of 2025 totaled $34.6 million, as compared to $3.8 million in the prior year. The change was primarily attributable to a non-cash loss of $25.8 million from the change in valuation of warrant liabilities, based on a Black-Scholes valuation method reflecting the increase in the Company's stock price from $0.91per share at December 31, 2024 to $2.25 at March 31, 2025. Article content Adjusted EBITDA, a non-IFRS measure, increased 169.2% to $(3.5) million in the first quarter of 2025, as compared to $(1.3) million in the same year-ago quarter Article content Cash and cash equivalents as of March 31, 2025 totaled $16.9 million, as compared to $7.8 million as of December 31, 2024. The change in cash was primarily a result of the receipt of proceeds of $8.7 million in conjunction with an equity placement, receipt of $3.3 million in conjunction with the exercise of warrants, partially offset by strategic investments in mining assets at the Company's Sangdong Project in South Korea. Subsequent to the close of the first quarter, the Company raised $3.6 million in proceeds from the exercise of additional warrants. Article content Almonty President & CEO Lewis Black commented: 'The first quarter was marked by solid execution on multiple fronts. At Panasqueira, we again delivered positive income from mining operations, reaffirming the mine's consistency and the importance of the operating experience derived there as we approach startup at our flagship Sangdong project in South Korea. Article content 'With processing equipment now installed and the final drawdown of the US$75.1 million KfW IPEX-Bank loan completed, Sangdong is effectively construction-complete. We're now entering the final pre-production phase at what is one of the largest, highest-grade tungsten projects outside of China. Given Sangdong's significantly higher ore grade compared to Panasqueira, the production economics are expected to be highly favorable. Article content 'We also reinforced our financial position, ending the quarter with nearly $17 million in cash, thanks to equity inflows and warrant exercises. The reported net loss includes a large non-cash charge of $25.8 million related to the revaluation of warrant liabilities – ironically driven by a sharply higher stock price, which more than doubled during the quarter. While this accounting treatment impacts reported earnings, it is entirely non-cash and is simply the reflection of IFRS accounting rules. Article content 'On the strategic front, we expanded our U.S. presence through a new partnership with American Defense International, supporting our role as a key allied supplier of tungsten. This was further reinforced by the signing of a binding offtake agreement with a U.S. defense contractor to supply tungsten oxide exclusively for use in American defense applications. We also launched a global investor communications program with MZ Group to ensure our value proposition is clearly understood by the capital markets. Article content 'With production at Sangdong on the near-term horizon, we believe Almonty is well positioned to enter a new phase of growth, aligned with rising strategic demand for tungsten in defense and technology applications,' concluded Black. Article content Almonty Industries Inc. (TSX: AII / ASX: AII / OTCQX: ALMTF / Frankfurt: ALI) is a diversified and experienced global producer of tungsten concentrate in conflict-free regions. The Company is currently mining, processing and shipping tungsten concentrate from its Panasqueira mine in Portugal. Its Sangdong tungsten mine in Gangwon Province, South Korea is currently under construction. The Sangdong mine was historically one of the largest tungsten mines in the world and one of the few long-life, high-grade tungsten deposits outside of China, and has significant upside potential from an underlying molybdenum deposit. Article content Additional development projects underway include the Valtreixal tin/tungsten project in northwestern Spain and Los Santos Mine in western Spain. Further information about Almonty's activities may be found at and under Almonty's profile at Article content The release, publication or distribution of this announcement in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this announcement is released, published or distributed should inform themselves about and observe such restrictions. Article content Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release. Article content This press release makes reference to certain non-GAAP financial measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement IFRS financial measures by providing further understanding of Almonty's results of operations from management's perspective. Almonty's definitions of non-GAAP measures used in this press release may not be the same as the definitions for such measures used by other companies in their reporting. Non-GAAP measures have (1)limitations as analytical tools and should not be considered in isolation nor as a substitute for analysis of Almonty's financial information reported under IFRS. Almonty uses non-GAAP financial measures, including 'EBITDA', to provide investors with supplemental measures of its operating performance and to eliminate items that have less bearing on operating performance or operating conditions, and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. Almonty defines 'EBITDA from mining operations' as gross revenue less mine production costs. Article content Almonty believes that securities analysts, investors and other interested parties frequently use non-GAAP financial measures in the evaluation of issuers. Almonty's management also uses non-GAAP financial measures in order to facilitate operating performance comparisons from period to period. Article content When used in this press release, the words 'estimate', 'project', 'belief', 'anticipate', 'intend', 'expect', 'plan', 'predict', 'may' or 'should' and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. These statements and information are based on management's beliefs, estimates and opinions on the date that statements are made and reflect Almonty's current expectations. Article content Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Almonty to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: any specific risks relating to fluctuations in the price of ammonium para tungstate ('APT') from which the sale price of Almonty's tungsten concentrate is derived, actual results of mining and exploration activities, environmental, economic and political risks of the jurisdictions in which Almonty's operations are located and changes in project parameters as plans continue to be refined, forecasts and assessments relating to Almonty's business, credit and liquidity risks, hedging risk, competition in the mining industry, risks related to the market price of Almonty's shares, the ability of Almonty to retain key management employees or procure the services of skilled and experienced personnel, risks related to claims and legal proceedings against Almonty and any of its operating mines, risks relating to unknown defects and impairments, risks related to the adequacy of internal control over financial reporting, risks related to governmental regulations, including environmental regulations, risks related to international operations of Almonty, risks relating to exploration, development and operations at Almonty's tungsten mines, the ability of Almonty to obtain and maintain necessary permits, the ability of Almonty to comply with applicable laws, regulations and permitting requirements, lack of suitable infrastructure and employees to support Almonty's mining operations, uncertainty in the accuracy of mineral reserves and mineral resources estimates, production estimates from Almonty's mining operations, inability to replace and expand mineral reserves, uncertainties related to title and indigenous rights with respect to mineral properties owned directly or indirectly by Almonty, the ability of Almonty to obtain adequate financing, the ability of Almonty to complete permitting, construction, development and expansion, challenges related to global financial conditions, risks related to future sales or issuance of equity securities, differences in the interpretation or application of tax laws and regulations or accounting policies and rules and acceptance of the TSX of the listing of Almonty shares on the TSX. Article content Forward-looking statements are based on assumptions management believes to be reasonable, including but not limited to, no material adverse change in the market price of ammonium para tungstate (APT), the continuing ability to fund or obtain funding for outstanding commitments, expectations regarding the resolution of legal and tax matters, no negative change to applicable laws, the ability to secure local contractors, employees and assistance as and when required and on reasonable terms, and such other assumptions and factors as are set out herein. Although Almonty has attempted to identify important factors that could cause actual results, level of activity, performance or achievements to differ materially from those contained in forward-looking statements, there may be other factors that cause results, level of activity, performance or achievements not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate and even if events or results described in the forward-looking statements are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, Almonty. Accordingly, readers should not place undue reliance on forward-looking statements and are cautioned that actual outcomes may vary. Article content Investors are cautioned against attributing undue certainty to forward-looking statements. Almonty cautions that the foregoing list of material factors is not exhaustive. When relying on Almonty's forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Article content Almonty has also assumed that material factors will not cause any forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. Article content The forward-looking information contained in this press release represents the expectations of Almonty as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While Almonty may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws. Article content Article content Article content Article content Contacts Article content Company Contact: Lewis Black Chairman, President and CEO (647) 438-9766 info@ Article content Article content Article content
Associated Press
06-05-2025
- Business
- Associated Press
Transcat Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
ROCHESTER, N.Y.--(BUSINESS WIRE)--May 6, 2025-- Transcat, Inc. (Nasdaq: TRNS) ('Transcat' or the 'Company'), a leading provider of mission critical calibration services and distributor of test and measurement equipment to Fortune 500 Manufacturers, today announced it has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Transcat management to develop and implement a comprehensive Investor and Media Relations strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight Transcat's market-leading position providing mission critical, accredited calibration services and equipment to a blue-chip client base, with the footprint and scale to support large national opportunities. Since 1964, clients served include a diverse set of industries in life sciences, aerospace and government/defense. Transcat's complementary business segments, combined with recent synergistic acquisitions, drove fiscal third quarter 2025 revenue of $66.8 million and full fiscal year 2024 growth of 13% to a record $259.5 million. High levels of recurring revenue streams in its Service segment have provided 63 consecutive quarters of revenue growth, and a gross margin of 34% in fiscal year 2024. Fiscal year 2024 Adjusted EBITDA of $38.6 million and net income of $13.6 million, up 28% from the prior year, further demonstrated the company's differentiated value proposition. With $19.3 million in operating free cash flow, access to $40.5 million available under an existing credit facility and low leverage ratio of only 0.97, Transcat is well positioned to build on its growth and M&A initiatives. MZ has developed a distinguished reputation as a premier resource for institutional investors, brokers, analysts, and private investors and maintains offices worldwide. Chris Tyson, Executive Vice President & Partner at MZ North America, along with Directors Larry Holub and Brooks Hamilton, will advise Transcat's investor relations team in all facets of investor relations, including, but not limited to, the coordination of roadshows and investment conferences across key cities and building brand awareness with financial and social media outlets. Chris Tyson commented: 'The stringent regulatory standards for manufacturers imposed by entities including the FDA, FAA and Department of Defense to ensure product safety and environmental protection are driving the need for high-value calibration services. Growth from the increasing deployment of industrial automated systems and advanced manufacturing technologies demands more precise instrumentation and control, while medical device usage in diagnostics, treatment, and monitoring increases calibration service requirements. Additionally, high-precision instrumentation and strict safety protocols in aviation and defense necessitate frequent, exacting calibration. Across these industries, Markets and Markets estimates the global calibration services market size will grow to $8.1 billion by 2030. In the short term, required calibration provides recurring revenue and earnings visibility in an uncertain market. Longer term, domestic initiatives to bring manufacturing back to the US, most immediately the pharmaceutical industry, will provide additional growth opportunities. With this tremendous revenue potential, we look forward to sharing the Transcat story with our network of institutional investors, family offices and retail investors.' 'This is an exciting time for Transcat with recent acquisitions expanding our geographic footprint, capabilities, markets, revenue and margin,' said Lee D. Rudow, President and CEO of Transcat. 'Namely, our recently acquired Martin Calibration business is increasing our Midwest service presence, which is rich in both life sciences and aerospace and defense manufacturing. This acquisition and pipeline of opportunities present compelling cross-sell synergies to drive revenue growth and margin into these acquired customer bases and our installed base. We look forward to working with Chris and the entire team at MZ Group to communicate our business milestones in the weeks and months ahead.' For more information on Transcat, please visit or the company's blog at . To schedule a conference call with management, please email your request to [email protected] or call Chris Tyson at 949-491-8235. About MZ MZ North America is the US division of MZ Group, a global leader in investor relations with over 250 employees and 800 clients across 12 different exchanges. For over 25 years, MZ has implemented award winning programs and developed a reputation for delivering tangible results for public and private companies via strategic communications, industry-leading investor outreach, public relations, a market intelligence desk, and a suite of technology solutions, spanning websites, conference call/webcasting, video production and XBRL/Edgar filing services. MZ maintains a global footprint with professionals located throughout every time zone in North America, as well as Taipei and São Paulo. For more information, please visit . About Transcat Transcat Inc. is a leading provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing best-in-class services and products to highly regulated industries, particularly the Life Science industry, which includes pharmaceutical, biotechnology, medical device, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. Transcat provides periodic on-site services, mobile calibration services, pickup and delivery, in-house services at its 33 Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Inclusive of customer embedded locations and other field offices, we operate out of more than 50 locations. The breadth and depth of measurement parameters addressed by Transcat's ISO/IEC 17025 scopes of accreditation are believed to be the best in the industry. Transcat also operates as a leading value-added distributor that markets, sells and rents new and used national and proprietary brand instruments to customers primarily in North America. The Company believes its combined Service and Distribution segment offerings, experience, technical expertise, and integrity create a unique and compelling value proposition for its customers. Transcat's strategy is to leverage its strong brand and unique value proposition that includes its comprehensive instrument service capabilities, enterprise asset management, and leading distribution platform to drive organic sales growth. The Company will also look to expand its addressable calibration market through acquisitions and capability investments to further realize the inherent leverage of its business model. More information about Transcat can be found at: . Safe Harbor Statement This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact and thus are subject to risks, uncertainties and assumptions. Forward-looking statements relate to expectations, estimates, beliefs, assumptions and predictions of future events and are identified by words such as 'aim,' 'anticipates,' 'believes,' 'can,' 'could,' 'designed,' 'estimates,' 'expects,' 'focus,' 'goal,' 'intends,' 'may,' 'plan,' 'outlook,' 'potential,' 'seek,' 'strategy,' 'strive,' 'target,' 'will,' 'would,' and other similar words. All statements addressing operating performance, events or developments that Transcat expects or anticipates will occur in the future, including but not limited to statements relating to anticipated revenue, profit margins, the commercialization of software projects, sales operations, capital expenditures, cash flows, operating income, growth strategy, segment growth, potential acquisitions, integration of acquired businesses, market position, customer preferences, outlook and changes in market conditions in the industries in which Transcat operates are forward-looking statements. Forward-looking statements should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties include those more fully described in Transcat's Annual Report and Quarterly Reports filed with the Securities and Exchange Commission, including under the heading entitled 'Risk Factors.' Should one or more of these risks or uncertainties materialize or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company's forward-looking statements, which speak only as of the date they are made. Except as required by law, the Company disclaims any obligation to update, correct or publicly announce any revisions to any of the forward-looking statements contained in this news release, whether as the result of new information, future events or otherwise. View source version on CONTACT: Investor Relations Chris Tyson Executive Vice President MZ Group - MZ North America 949-491-8235 [email protected] KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: OTHER DEFENSE PHARMACEUTICAL UTILITIES ENERGY MEDICAL DEVICES DEFENSE PUBLIC RELATIONS/INVESTOR RELATIONS BIOTECHNOLOGY COMMUNICATIONS AEROSPACE MANUFACTURING HEALTH SOURCE: Transcat, Inc. Copyright Business Wire 2025. PUB: 05/06/2025 08:31 AM/DISC: 05/06/2025 08:32 AM
Business Wire
06-05-2025
- Business
- Business Wire
Transcat Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat, Inc. (Nasdaq: TRNS) ('Transcat' or the 'Company'), a leading provider of mission critical calibration services and distributor of test and measurement equipment to Fortune 500 Manufacturers, today announced it has engaged international investor relations specialists MZ Group (MZ) to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Transcat management to develop and implement a comprehensive Investor and Media Relations strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight Transcat's market-leading position providing mission critical, accredited calibration services and equipment to a blue-chip client base, with the footprint and scale to support large national opportunities. Since 1964, clients served include a diverse set of industries in life sciences, aerospace and government/defense. Transcat's complementary business segments, combined with recent synergistic acquisitions, drove fiscal third quarter 2025 revenue of $66.8 million and full fiscal year 2024 growth of 13% to a record $259.5 million. High levels of recurring revenue streams in its Service segment have provided 63 consecutive quarters of revenue growth, and a gross margin of 34% in fiscal year 2024. Fiscal year 2024 Adjusted EBITDA of $38.6 million and net income of $13.6 million, up 28% from the prior year, further demonstrated the company's differentiated value proposition. With $19.3 million in operating free cash flow, access to $40.5 million available under an existing credit facility and low leverage ratio of only 0.97, Transcat is well positioned to build on its growth and M&A initiatives. MZ has developed a distinguished reputation as a premier resource for institutional investors, brokers, analysts, and private investors and maintains offices worldwide. Chris Tyson, Executive Vice President & Partner at MZ North America, along with Directors Larry Holub and Brooks Hamilton, will advise Transcat's investor relations team in all facets of investor relations, including, but not limited to, the coordination of roadshows and investment conferences across key cities and building brand awareness with financial and social media outlets. Chris Tyson commented: "The stringent regulatory standards for manufacturers imposed by entities including the FDA, FAA and Department of Defense to ensure product safety and environmental protection are driving the need for high-value calibration services. Growth from the increasing deployment of industrial automated systems and advanced manufacturing technologies demands more precise instrumentation and control, while medical device usage in diagnostics, treatment, and monitoring increases calibration service requirements. Additionally, high-precision instrumentation and strict safety protocols in aviation and defense necessitate frequent, exacting calibration. Across these industries, Markets and Markets estimates the global calibration services market size will grow to $8.1 billion by 2030. In the short term, required calibration provides recurring revenue and earnings visibility in an uncertain market. Longer term, domestic initiatives to bring manufacturing back to the US, most immediately the pharmaceutical industry, will provide additional growth opportunities. With this tremendous revenue potential, we look forward to sharing the Transcat story with our network of institutional investors, family offices and retail investors.' 'This is an exciting time for Transcat with recent acquisitions expanding our geographic footprint, capabilities, markets, revenue and margin,' said Lee D. Rudow, President and CEO of Transcat. 'Namely, our recently acquired Martin Calibration business is increasing our Midwest service presence, which is rich in both life sciences and aerospace and defense manufacturing. This acquisition and pipeline of opportunities present compelling cross-sell synergies to drive revenue growth and margin into these acquired customer bases and our installed base. We look forward to working with Chris and the entire team at MZ Group to communicate our business milestones in the weeks and months ahead.' For more information on Transcat, please visit or the company's blog at To schedule a conference call with management, please email your request to TRNS@ or call Chris Tyson at 949-491-8235. About MZ MZ North America is the US division of MZ Group, a global leader in investor relations with over 250 employees and 800 clients across 12 different exchanges. For over 25 years, MZ has implemented award winning programs and developed a reputation for delivering tangible results for public and private companies via strategic communications, industry-leading investor outreach, public relations, a market intelligence desk, and a suite of technology solutions, spanning websites, conference call/webcasting, video production and XBRL/Edgar filing services. MZ maintains a global footprint with professionals located throughout every time zone in North America, as well as Taipei and São Paulo. For more information, please visit About Transcat Transcat Inc. is a leading provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing best-in-class services and products to highly regulated industries, particularly the Life Science industry, which includes pharmaceutical, biotechnology, medical device, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. Transcat provides periodic on-site services, mobile calibration services, pickup and delivery, in-house services at its 33 Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Inclusive of customer embedded locations and other field offices, we operate out of more than 50 locations. The breadth and depth of measurement parameters addressed by Transcat's ISO/IEC 17025 scopes of accreditation are believed to be the best in the industry. Transcat also operates as a leading value-added distributor that markets, sells and rents new and used national and proprietary brand instruments to customers primarily in North America. The Company believes its combined Service and Distribution segment offerings, experience, technical expertise, and integrity create a unique and compelling value proposition for its customers. Transcat's strategy is to leverage its strong brand and unique value proposition that includes its comprehensive instrument service capabilities, enterprise asset management, and leading distribution platform to drive organic sales growth. The Company will also look to expand its addressable calibration market through acquisitions and capability investments to further realize the inherent leverage of its business model. More information about Transcat can be found at: Safe Harbor Statement This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact and thus are subject to risks, uncertainties and assumptions. Forward-looking statements relate to expectations, estimates, beliefs, assumptions and predictions of future events and are identified by words such as 'aim,' 'anticipates,' 'believes,' 'can,' 'could,' 'designed,' 'estimates,' 'expects,' 'focus,' 'goal,' 'intends,' 'may,' 'plan,' 'outlook,' 'potential,' 'seek,' 'strategy,' 'strive,' 'target,' 'will,' 'would,' and other similar words. All statements addressing operating performance, events or developments that Transcat expects or anticipates will occur in the future, including but not limited to statements relating to anticipated revenue, profit margins, the commercialization of software projects, sales operations, capital expenditures, cash flows, operating income, growth strategy, segment growth, potential acquisitions, integration of acquired businesses, market position, customer preferences, outlook and changes in market conditions in the industries in which Transcat operates are forward-looking statements. Forward-looking statements should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties include those more fully described in Transcat's Annual Report and Quarterly Reports filed with the Securities and Exchange Commission, including under the heading entitled 'Risk Factors.' Should one or more of these risks or uncertainties materialize or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company's forward-looking statements, which speak only as of the date they are made. Except as required by law, the Company disclaims any obligation to update, correct or publicly announce any revisions to any of the forward-looking statements contained in this news release, whether as the result of new information, future events or otherwise.
Associated Press
12-03-2025
- Business
- Associated Press
Flux Power to Host Fiscal First and Second Quarter 2025 Results Conference Call on Thursday, March 20, 2025 at 4:30 p.m. Eastern Time
VISTA, Calif.--(BUSINESS WIRE)--Mar 12, 2025-- Flux Power Holdings, Inc. (NASDAQ: FLUX), a developer of advanced lithium-ion energy storage solutions for electrification of commercial and industrial equipment, will hold a conference call on March 20, 2025, at 4:30 p.m. Eastern Time to discuss its results for the fiscal first and second quarters ended September 30, 2024, and December 31, 2024, respectively. A press release detailing these results will be issued prior to the call. Flux Power Senior Advisor and former CEO Ron Dutt to provide business updates, current CEO Krishna Vanka will speak to his background and vision for the Company, CFO Kevin Royal will provide a review of the fiscal first and second quarters, and CRO Kelly Frey will provide an update on new customers and customer acquisition initiatives. The conference call will be followed by a question-and-answer session and accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company's website here. To access the call, please use the following information: Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235. The conference call will be broadcast live and available for replay at and via the investor relations section of the Company's website here. A replay of the webcast will be available after 7:30 p.m. Eastern Time through June 20, 2025. About Flux Power Holdings, Inc. Flux Power (NASDAQ: FLUX) designs, manufactures, and sells advanced lithium-ion energy storage solutions for electrification of a range of industrial and commercial sectors including material handling, airport ground support equipment (GSE), and stationary energy storage. Flux Power's lithium-ion battery packs, including the proprietary battery management system (BMS) and telemetry, provide customers with a better performing, lower cost of ownership, and more environmentally friendly alternative, in many instances, to traditional lead acid and propane-based solutions. Lithium-ion battery packs reduce CO2 emissions and help improve sustainability and ESG metrics for fleets. For more information, please visit [email protected] [email protected] Investor Relations: Chris Tyson, Executive Vice President MZ Group - MZ North America 949-491-8235 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: OTHER ENERGY TECHNOLOGY MANUFACTURING BATTERIES ENERGY OTHER MANUFACTURING SOURCE: Flux Power Holdings, Inc. Copyright Business Wire 2025. PUB: 03/12/2025 08:31 AM/DISC: 03/12/2025 08:32 AM
